ArticleResearch and reports in urology2026

Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark Study.

Nobuki Furubayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.